The risk of infections in psoriasis patients treated with biologics during the COVID-19 pandemic
In this MEDtalk Lara Van Der Schoot and Juul van den Reek, both Radboud Institute for Health Sciences and Department of Dermatology, The Netherlands, discuss the risk of COVID-19 in psoriasis patients treated with biologics, and whether there is a differential risk of infections between the biologics targeting different interleukins.
